Sign in

    Jeroen Van den Bossche

    Financial Analyst – Equity at KBC Securities

    Jeroen Van den Bossche is a Financial Analyst – Equity at KBC Securities NV, specializing in the coverage of European pharmaceuticals and biotechnology companies, including notable firms such as Amoéba, UCB, and Galapagos. Since joining KBC Securities in July 2021, he has contributed actionable insights and research that support institutional investment decisions, leveraging experience previously gained as a Private Equity Investor at Participatiemaatschappij Vlaanderen NV. While public rankings or success metrics such as TipRanks scores are not available, his analyst role is supported by published company notes and active participation in earnings calls across leading sector names. Van den Bossche holds credentials appropriate for regulated securities research in Belgium as indicated by KBC’s FSMA oversight, and his career trajectory highlights expertise in both asset management and equity analysis within the life sciences sector.

    Jeroen Van den Bossche's questions to Inventiva (IVA) leadership

    Jeroen Van den Bossche's questions to Inventiva (IVA) leadership • Q4 2021

    Question

    Jeroen Van den Bossche of KBC Securities asked about the rationale for the LEGEND combination trial, questioning if it was based solely on existing clinical data for lanifibranor and empagliflozin or if new preclinical data was used. He also inquired about the company's future commercialization strategy for lanifibranor, cedirogant, and odiparcil, specifically whether they plan to partner or go to market themselves.

    Answer

    CMO Michael Cooreman and executive Pierre Broqua explained that the strong rationale for the combination is built upon extensive existing human clinical data and the well-understood mechanisms of both drugs, making new non-clinical studies unnecessary. Executive Frederic Cren outlined the strategy: find a big pharma partner for lanifibranor, likely after Phase III data; cedirogant development is fully managed and funded by AbbVie; and for odiparcil, the company continues to seek a partner due to resource constraints.

    Ask Fintool Equity Research AI